PT  - JOURNAL ARTICLE
AU  - Ana Patrícia Domingues
AU  - Fernando Mota
AU  - Marta DurÃO
AU  - Cristina Frutuoso
AU  - Natália Amaral
AU  - Carlos Freire De Oliveira
TI  - Neoadjuvant Chemotherapy in Advanced Vulvar Cancer
AID  - 10.1111/IGC.0b013e3181c93adc
DP  - 2010 Feb 01
TA  - International Journal of Gynecologic Cancer
PG  - 294-298--294-298
VI  - 20
IP  - 2
4099  - http://ijgc.bmj.com/content/20/2/294-298.short
4100  - http://ijgc.bmj.com/content/20/2/294-298.full
SO  - Int J Gynecol Cancer2010 Feb 01; 20
AB  - Introduction: Locally advanced tumors of the vulva represent approximately one third of all vulvar cancers. Therapeutic options include chemoradiation, radiotherapy, and neoadjuvant chemotherapy (NACT).Materials and Methods: Analysis of 3 NACT schemes, bleomicine, paclitaxel, and 5-fluorouracil/cisplatin, used in patients with locally advanced vulvar tumors in a 12-year period. The following parameters were evaluated and compared between regimens: age, initial tumor size, inguinal involvement, histological type, toxicities, response to treatment, surgery performed after NACT, and overall survival.Results: Of the 25 patients included, 10 underwent an NACT regimen with bleomicine (Group A); 5, with paclitaxel (Group B); and 10, with a combination of 5-fluorouracil/cisplatin (Group C). In Group A, there was a 60% response rate. Mortality was 70%, with an overall survival rate of 70%, 40%, and 30% at 12, 24, and 60 months, respectively. The mean (SD) survival was 46.7 (15.4) months. In Group B, the response rate was 40%, with an 80% mortality rate and a survival rate of 60% and 20% at 12 and 24 months, respectively. The mean (SD) survival was 17.0 (3.8) months. In Group C, 20% of the responses were observed and the mortality was 90%, with an overall survival rate of 10% at 12 and 24 months and a mean (SD) survival of 7.6 (2.0) months.Conclusion: The best response and overall survival rates were achieved in Group A with the NACT scheme of bleomicine.